Last reviewed · How we verify
EPOCH
EPOCH, developed by the National Cancer Institute (NCI), is a marketed small molecule with a key composition patent expiring in 2028. Its primary strength lies in its interaction with specific biological pathways, offering targeted therapeutic effects. The primary risk is the lack of revenue data and key trial results, which may limit its market visibility and competitive positioning.
At a glance
| Generic name | EPOCH |
|---|---|
| Also known as | Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride |
| Sponsor | National Cancer Institute (NCI) |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent Thalassemia (PHASE2)
- Inspiratory Muscle Training in Lung Transplant Candidates (NA)
- A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood (PHASE1)
- SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
- A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH) (PHASE3)
- The Safety and Effectiveness of Q Therapeutic System, Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Patients With Chronic Stroke. (NA)
- Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (PHASE2)
- Using Middle School Science Teachers to Address Cancer Health Disparities (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |